Home » Topics » Infection, BioWorld Science

Infection, BioWorld Science
RSS

Phase III trial of Neuprex in meningococcemia continues; pilot trial in CF begins

Sep. 25, 1997

LY-303366: efficacy in rabbits with invasive pulmonary aspergillosis

Sep. 25, 1997

Famvir approved by FDA for new indication

Sep. 22, 1997

Vaxar: first launch for new fluoroquinolone

Sep. 22, 1997

Phase I results reported for MiKasome

Sep. 22, 1997

New cephalosporins from Il-Dong

Sep. 19, 1997

Searle evaluates novel target for antifungal agents

Sep. 17, 1997

Antiviral benzimidazole compounds prepared at Glaxo Wellcome

Sep. 17, 1997

Takeda claims new carbapenems

Sep. 17, 1997

Eisai discovers potent, optically active triazole antifungal

Sep. 16, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.